CIK 0000899923
- Accelerated filer
MYRIAD GENETICS INC
Sign in to watch- Ticker
- MYGN
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 870494517
- Phone
- +1 801-584-3600
- Business address
- 322 NORTH 2200 WEST, SALT LAKE CITY, UT, 84116
- Former names
- MYRIAD GENETICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $34,252
- in 1 filing
Net −$34,252. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-09-17 | Capone Mark Christopher President & C.E.O. | Returned to the company | −11,025 | $46.35 | $511K | 321,150 |
| 2018-09-17 | Sanders Walter Lloyd President Myriad Oncology | Returned to the company | −844 | $46.35 | $39K | 24,117 |
| 2018-09-17 | LANCHBURY JERRY S Chief Scientific Officer | Returned to the company | −6,515 | $46.35 | $302K | 132,294 |
| 2018-09-17 | MARSH RICHARD M E.V.P., General Counsel | Returned to the company | −6,314 | $46.35 | $293K | 110,260 |
| 2018-07-11 | Capone Mark Christopher President & C.E.O. | Exercise or conversion | +77,654 | $30.12 | $2.3M | 409,829 |
| 2018-07-11 | Capone Mark Christopher President & C.E.O. | Sale | −77,654 | $41.00 | $3.2M | 332,175 |
| 2018-07-11 | Capone Mark Christopher President & C.E.O. | Exercise or conversion | +2,346 | $30.12 | $71K | 334,521 |
| 2018-07-11 | Capone Mark Christopher President & C.E.O. | Sale | −2,346 | $41.00 | $96K | 332,175 |
| 2018-07-11 | Capone Mark Christopher President & C.E.O. | Exercise or conversion · Incentive Stock Option (right to buy) | −2,346 | 0 | ||
| 2018-07-11 | Capone Mark Christopher President & C.E.O. | Exercise or conversion · Non-Qualified Stock Option (right to buy) | −77,654 | 0 | ||
| 2018-07-11 | HENDERSON JOHN T Director | Exercise or conversion | +10,000 | $24.39 | $244K | 59,743 |
| 2018-07-11 | HENDERSON JOHN T Director | Sale | −10,000 | $44.00 | $440K | 49,743 |
| 2018-07-11 | HENDERSON JOHN T Director | Exercise or conversion | +10,000 | $24.39 | $244K | 59,743 |
| 2018-07-11 | HENDERSON JOHN T Director | Sale | −10,000 | $42.01 | $420K | 49,743 |
| 2018-07-11 | HENDERSON JOHN T Director | Exercise or conversion | +10,000 | $24.39 | $244K | 59,743 |
| 2018-07-11 | HENDERSON JOHN T Director | Sale | −10,000 | $40.17 | $402K | 49,743 |
| 2018-07-11 | HENDERSON JOHN T Director | Exercise or conversion · Non-Qualified Stock Option (right to buy) | −10,000 | 20,000 | ||
| 2018-07-11 | HENDERSON JOHN T Director | Exercise or conversion · Non-Qualified Stock Option (right to buy) | −10,000 | 10,000 | ||
| 2018-07-11 | HENDERSON JOHN T Director | Exercise or conversion · Non-Qualified Stock Option (right to buy) | −10,000 | 0 | ||
| 2018-07-11 | LANCHBURY JERRY S Chief Scientific Officer | Exercise or conversion | +46,139 | $30.34 | $1.4M | 184,948 |
Page 40 of 60 · 1,194 trades